Atlas Trials

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Clinical trial NCT01650779 · COMPLETED

Trial details

NCT number
NCT01650779
Sponsor
Genzyme, a Sanofi Company
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Fabry Disease
Start date
2012-04-01
Primary completion
2013-03-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.